Merck

[Treatment outcome of peptide vaccination for advanced colorectal cancer].

Gan to kagaku ryoho. Cancer & chemotherapy (2014-01-08)
Fumiaki Sugiura, Keisuke Inoue, Akihiro Kogita, Yasumasa Yoshioka, Jinichi Hida, Kiyotaka Okuno, Yasushi Sukegawa
RESUMO

Complementary DNA( cDNA) microarray technology coupled with laser microdissection has been used to identify human leukocyte antigen (HLA)-A24-restricted epitope peptides as potential targets for cancer vaccination in colorectal cancer patients. These antigenic peptides were derived from 2 different cancer-testis antigens, ring finger protein 43 (RNF43) and translocase of outer mitochondrial membrane 34( TOMM34). We conducted a clinical trial of colorectal cancer-specific peptide( RNF43, TOMM34) vaccines with uracil/tegafur( UFT)+Leucovorin( LV) for the treatment of advanced or recurrent colorectal cancer. The vaccinations were well tolerated without any serious adverse events. There were long-term survivors in the group showing cytotoxic T lymphocyte (CTL) responses against both RNF43 and TOMM34, as well as in the group showing CTL responses against either RNF43 or TOMM34. A new study has been planned to obtain more immunological responses. We started a clinical trial of vaccines against multiple peptides (RNF43, TOMM34, forkhead box protein M1 [FOXM1], maternal embryonic leucine zipper kinase [MELK], holliday junction recognition protein[HJURP], vascular endothelial growth factor receptor 1[VEGFR1], and VEGFR2) for the treatment of advanced or recurrent colorectal cancer.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Uracil, ≥99.0%
Sigma-Aldrich
Uracil, BioReagent, suitable for cell culture
Supelco
Folinic acid calcium salt hydrate, analytical standard
Sigma-Aldrich
Folinic acid calcium salt hydrate, BioXtra, ≥99.0% (HPLC)